Core Points - Anbiping announced the approval of a cash management plan using its own funds up to RMB 220 million [2] - The cash management will focus on high safety, good liquidity, and low-risk investment products [2] - The approved investment products include structured deposits, time deposits, notice deposits, large certificates of deposit, and agreed deposits [2] - The funds can be used in a rolling manner within the approved limit and must not be used for pledging or securities investment purposes [2] - The usage period for the funds is valid for 12 months from the date of board approval [2]

Core Viewpoint - The company announced a temporary adjustment to the use of idle space from fundraising investment projects, allowing for the leasing of part of the marketing service network upgrade construction project [1] Group 1 - The company will hold the fourth board of directors' ninth meeting and the fourth supervisory board's ninth meeting on August 21, 2025 [1] - The proposal regarding the temporary adjustment of idle space usage requires approval from the company's shareholders' meeting [1]

Core Viewpoint - Anping announced the approval of a plan to utilize idle raised funds for cash management, with a limit of up to RMB 140 million, ensuring that it does not affect the normal investment plans of the raised funds [1] Group 1 - The company will use the idle funds for purchasing high-security, high-liquidity investment products, including but not limited to structured deposits, time deposits, notice deposits, large certificates of deposit, and agreed deposits [1] - The cash management products cannot be used for pledging or for investment purposes in securities [1] - The funds within the approved limit can be used in a rolling manner, and the usage period is valid for 12 months from the date of board approval [1]

Core Insights - Anbiping reported a significant decline in revenue and net profit for the first half of 2025, indicating financial challenges faced by the company [1] Financial Performance - The company achieved operating revenue of 159,397,066.02 yuan, representing a year-on-year decrease of 30.11% [1] - The net profit attributable to shareholders was -12,498,511.13 yuan, reflecting a year-on-year decline of 176.38% [1]

Group 1 - The core point of the article is that Anbiping announced the approval of multiple proposals during the ninth meeting of its fourth supervisory board [2] Group 2 - The announcement was made on the evening of August 21 [2] - The proposals included the company's summary and other related matters [2]

Group 1 - The company Anbiping (688393) reported a revenue of 159 million yuan for the first half of 2025, representing a year-on-year decline of 30.11% [1] - The net profit attributable to shareholders turned negative, amounting to -12.4985 million yuan, indicating a shift from profit to loss compared to the previous year [1] - The basic earnings per share were reported at -0.13 yuan [1]

Core Points - The company Anbiping (688393.SH) plans to use up to RMB 140 million of temporarily idle raised funds for cash management, ensuring that it does not affect the normal progress of fundraising investment plans [1] Group 1 - The company will utilize the funds within the specified limit for rolling use during the investment period [1]

Core Viewpoint - The company has completed the fundraising project for the application development of a tumor companion diagnostic technology platform and has decided to conclude the project, utilizing the raised funds effectively [1] Group 1 - The company has fully utilized the raised funds for the project, achieving the main research and development goals [1] - The remaining raised funds amounting to 14,800 yuan will be permanently added to the company's working capital [1]

Core Viewpoint - Anbiping (688393.SH) plans to use up to RMB 140 million of temporarily idle raised funds for cash management without affecting the normal operation of its fundraising investment plan [1] Group 1 - The company will utilize the idle funds within a specified limit for cash management purposes [1] - The funds can be used in a rolling manner during the investment period [1]

Meeting Overview - The fourth session of the Supervisory Board of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. was held on August 21, 2025, combining in-person and remote participation [1] - The meeting was convened by Chairwoman Jin Xinyu, with all three supervisors participating in the voting [1] Resolutions Passed - The Supervisory Board approved the "2025 Half-Year Report" and its summary, confirming that the report accurately reflects the company's financial status and operational results for the reporting period [1][2] - The board also approved the "Special Report on the Storage and Actual Use of Raised Funds for the First Half of 2025," which disclosed the management of raised funds without any misappropriation or harm to shareholder interests [2] - Approval was granted for the use of up to 140 million yuan of temporarily idle raised funds for cash management, ensuring compliance with relevant regulations and not affecting the normal implementation of investment projects [3] - The board agreed to temporarily adjust the use of idle spaces from fundraising investment projects for external leasing, which aligns with the company's operational stability [4]